Nitrol 20mg Injection

The human body reacts differently to Nitrol 20mg Injection. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention.

Some of the common side effects of Innotubilin Injection:

• Absence of menstrual periods
  
• Anemia (low number of red blood cells)
  
• Decreased white blood cell count
  
• Hair loss
  
• Nausea
  
• Vomiting

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• The recommended dose of Nitrol 20mg Injection may vary according to the type of disease, as well as age, weight, and other health factors of the patients.
• It should be given intravenously by a doctor or experienced nurse.
• Don't self- administer the injection and don't double the dose to compensate for the missed dose.
  

• Nitrol 20mg Injection is a prescription based anticancer drug.
• It contains Mitoxantrone as an active ingredient which is a dark blue antineoplastic agent (chemotherapy drug) and immunosuppressant.
• It works by damaging the genetic material (DNA) of the cancer cells that promote growth of cancer cells and eventually destroying them.
  

• Preethi, S., Kumar, H. I. T. E. S. H., Rawal, V. B., Ajmeer, R. A. M. K. I. S. H. A. N., & Jain, V. I. K. A. S. (2022). Overview of mitoxantrone-a potential candidate for treatment of breast cancer. Int. J. Appl. Pharm, 14, 10-22.
  
• Neidhart, J. A., Gochnour, D., Roach, R., Hoth, D., & Young, D. (1986). A comparison of mitoxantrone and doxorubicin in breast cancer. Journal of Clinical Oncology, 4(5), 672-677.
  
• Foss-Abrahamsen, A., Lenner, P., Hedenus, M., Landys, K., & Noppa, H. (1987). Mitoxantrone in the Treatment of Patients With Non-Hodgkin's Lymphoma¹. Cancer treatment reports, 71(12), 1209.
  
• Poirier, T. I. (1986). Mitoxantrone. Drug intelligence & clinical pharmacy, 20(2), 97-105.
  
• Hagemeister, F., Cabanillas, F., Coleman, M., Gregory, S. A., & Zinzani, P. L. (2005). The role of mitoxantrone in the treatment of indolent lymphomas. The Oncologist, 10(2), 150-159.
  
• Silver, R. T., Case Jr, D. C., Wheeler, R. H., Miller, T. P., Stein, R. S., Stuart, J. J., ... & Costanzi. (1991). Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. Journal of clinical oncology, 9(5), 754-761.
  
• Landys, K. E. (1988). Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma. Investigational New Drugs, 6(2), 105-113.​